REGN insider trading — Regeneron Pharmaceuticals, Inc.
No open-market insider purchases or sales were filed for Regeneron Pharmaceuticals, Inc. (REGN) in the last 90 days. Other insider transactions — such as stock awards, option exercises or tax withholding — are listed below.
Updated Oct 16, 2026.
Recent REGN insider transactions
Every Form 4 filed by Regeneron Pharmaceuticals, Inc. officers, directors and 10% owners in the last 90 days, newest first. P = open-market purchase, S = open-market sale; other codes are awards, option exercises, tax withholding or gifts.
| Trade date | Insider | Role | Type | Ownership | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|---|
| Oct 14, 2026 | Murphy Andrew J | Co-Chief Scientific Officer | S · Sale · 10b5-1 | Direct | 4,147 | $772.70 | $3.20M | Form 4 |
| Oct 13, 2026 | Murphy Andrew J | Co-Chief Scientific Officer | M · Option exercise · 10b5-1 | Direct | 17,000 | $381.92 | $6.49M | Form 4 |
| Oct 13, 2026 | Murphy Andrew J | Co-Chief Scientific Officer | F · Tax withholding · 10b5-1 | Direct | 12,853 | $754.58 | $9.70M | Form 4 |
| Sep 3, 2026 | Mccourt Marion | EVP Commercial | S · Sale · 10b5-1 | Direct | 1,131 | $857.39 | $970K | Form 4 |
| Sep 2, 2026 | Mccourt Marion | EVP Commercial | S · Sale · 10b5-1 | Direct | 1,215 | $850.00 | $1.03M | Form 4 |
| Sep 2, 2026 | Guarini Kathryn | Director | M · Option exercise · 10b5-1 | Direct | 400 | $719.37 | $288K | Form 4 |
| Sep 2, 2026 | Guarini Kathryn | Director | S · Sale · 10b5-1 | Direct | 400 | $850.00 | $340K | Form 4 |
| Aug 19, 2026 | Larosa Joseph J | EVP General Counsel and Secret | M · Option exercise | Direct | 12,282 | $381.92 | $4.69M | Form 4 |
| Aug 19, 2026 | Larosa Joseph J | EVP General Counsel and Secret | F · Tax withholding | Direct | 9,019 | $830.15 | $7.49M | Form 4 |
| Aug 18, 2026 | Fenimore Christopher R. | EVP Finance CFO | M · Option exercise | Direct | 6,283 | $381.92 | $2.40M | Form 4 |
| Aug 18, 2026 | Fenimore Christopher R. | EVP Finance CFO | F · Tax withholding | Direct | 4,599 | $813.47 | $3.74M | Form 4 |
| Aug 10, 2026 | Guarini Kathryn | Director | M · Option exercise · 10b5-1 | Direct | 400 | $719.37 | $288K | Form 4 |
| Aug 10, 2026 | Guarini Kathryn | Director | S · Sale · 10b5-1 | Direct | 400 | $800.00 | $320K | Form 4 |
| Aug 10, 2026 | Zoghbi Huda Y | Director | M · Option exercise · 10b5-1 | Direct | 800 | $376.69 | $301K | Form 4 |
| Aug 10, 2026 | Zoghbi Huda Y | Director | S · Sale · 10b5-1 | Direct | 800 | $800.00 | $640K | Form 4 |
REGN insider trading FAQ
Are insiders buying REGN stock?
Not on the open market. In the last 90 days, Regeneron Pharmaceuticals, Inc. insiders made no open-market purchases, and no open-market sales. Purchases with the insider's own money are generally seen as a stronger signal than sales, which happen for many reasons (taxes, diversification, planned 10b5-1 sales).
Who are the insiders trading REGN?
No insider bought or sold on the open market in the last 90 days.
Where does REGN insider trading data come from?
Every transaction comes from SEC Form 4 filings on EDGAR. Company officers, directors and 10% owners must file a Form 4 within two business days of buying or selling. InsiderBolt reads these filings directly from the SEC.
More stocks with insider activity
Insider trading data is for informational purposes only and is not investment advice. Filings can be amended; always confirm details on SEC EDGAR.